These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 11820414

  • 1. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P, Tammela T, FinnBladder Group.
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [Abstract] [Full Text] [Related]

  • 2. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP, Aine R, Kylmälä T, Kallio J, Liukkonen T, Tammela T, Finnbladder Group.
    Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
    [Abstract] [Full Text] [Related]

  • 3. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL, Martín García B, de Diego Rodríguez E, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Rado Velázquez MA.
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [Abstract] [Full Text] [Related]

  • 4. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP, Aine RA, Kaasinen ES, Liukkonen TJ, Kylmälä TM, Huhtala H, Tammela TL, Finnbladder Group.
    Scand J Urol Nephrol; 2002 Oct; 36(3):213-7. PubMed ID: 12201938
    [Abstract] [Full Text] [Related]

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Oct; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 6. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 7. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J, Rodríguez-Martínez JJ, Barmadah SE, García Rodríguez J, Allende DM, Jalon A, Gonzalez R, Alvarez-Múgica M.
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [Abstract] [Full Text] [Related]

  • 8. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A, Sternberg CN, Rossetti A, Van Rijn A, Deidda A, Giannarelli D, Pansadoro V.
    Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 11. Noninvasive detection of bladder cancer with the BTA stat test.
    Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I.
    J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A, Aaltomaa S, Ala-Opas M.
    Ann Chir Gynaecol; 1999 Feb; 88(4):304-7. PubMed ID: 10661829
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B, Mommsen S, Svanholm H.
    Ugeskr Laeger; 1999 Apr 05; 161(14):2071-3. PubMed ID: 10354792
    [Abstract] [Full Text] [Related]

  • 17. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, van Exsel AJ, Kirkels WJ, Bangma C, van der Kwast TH.
    Eur Urol; 2009 Mar 05; 55(3):659-67. PubMed ID: 18501499
    [Abstract] [Full Text] [Related]

  • 18. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP, FinnBladder Group.
    World J Urol; 2008 Feb 05; 26(1):45-50. PubMed ID: 18180926
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ.
    J Urol; 1999 Feb 05; 161(2):388-94. PubMed ID: 9915409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.